DISCUSSION OF ORAL ABSTRACT SESSION 4 – NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE
CHAIR
Joseph Eron
University of North Carolina, Chapel Hill, NC, USA
OA4: DISCOVERY OF NOVEL POTENT HIV CAPSID INHIBITORS WITH LONG-ACTING POTENTIAL
Winston Tse
Gilead Scis, Inc, Foster City, CA, USA
OA4: RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIR WITH FTC/TAF FOR INITIAL HIV THERAPY
Paul Sax
Brigham and Women's Hosp, Boston, MA, USA
OA4: PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN THE ANRS 12249 TASP TRIAL
Anne Derache
Africa Hlth Rsr Inst, Mtubatuba, South Africa
OA4: PHASE III SWORD 1&2: SWITCH TO DTG+RPV MAINTAINS VIROLOGIC SUPPRESSION THROUGH 48 WKS
Josep M. Llibre
Univ Hosp Germans Trias, Badalona, Barcelona, Spain